首页> 外国专利> BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE

BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE

机译:基于BRCA1的乳腺癌或卵巢癌预防剂及其使用方法

摘要

A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically acceptable salt thereof, or analog thereof, and a pharmaceutically acceptable carrier containing the compound. The pharmaceutically acceptable carrier can be configured for oral, systemic, transdermal, intranasal, suppository, parenteral, intramuscular, intravenous, or subcutaneous administration. The compound can be present in the composition in a therapeutically effective amount for treating, inhibiting, and/or preventing breast and/or ovarian cancer. Also, the compound can be present in a therapeutically effective amount for enhancing production of BRCA1.
机译:用于治疗,抑制和/或预防乳腺癌和/或卵巢癌的药物组合物可以包括:具有化合物1-38之一,其药学上可接受的盐或其类似物以及药学上可接受的载体的结构的分子。包含该化合物。药学上可接受的载体可以被配置用于口服,全身,透皮,鼻内,栓剂,肠胃外,肌肉内,静脉内或皮下施用。该化合物可以治疗有效量存在于组合物中,用于治疗,抑制和/或预防乳腺癌和/或卵巢癌。同样,该化合物可以治疗有效量存在以增强BRCA1的产生。

著录项

  • 公开/公告号EP2214664A4

    专利类型

  • 公开/公告日2013-01-09

    原文格式PDF

  • 申请/专利权人 UNIVERSITY OF KANSAS;

    申请/专利号EP20080850217

  • 申请日2008-11-14

  • 分类号A61K31/403;A61K31/13;A61K31/164;A61K31/34;A61K31/343;A61K31/381;A61K31/4035;A61K31/41;A61K31/415;A61K31/4184;A61K31/423;A61K31/4245;A61K31/426;A61K31/44;A61K31/4709;A61K31/505;A61K31/5375;A61P35;C12N5;

  • 国家 EP

  • 入库时间 2022-08-21 16:34:09

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号